Development of a transferrin receptor-targeting HVXE vector

被引：23

作者：

Shimbo, Takashi ^{[1
]}

Kawachi, Masako ^{[1
]}

Saga, Kotaro ^{[1
]}

Fujita, Hiroshi ^{[1
]}

Yamazaki, Takehiko ^{[1
]}

Tanial, Katsuto ^{[1
]}

Kaneda, Yasufunii ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, Suita, Osaka 5650871, Japan

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2007年 / 364卷 / 03期

关键词：

HVJ-E; transferrin; targeting; cancer therapy;

D O I：

10.1016/j.bbrc.2007.09.135

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The development of more effective cancer treatments is anticipated. Tumor-targeted drug delivery is an important strategy in cancer therapy. We have developed an HVJ (hem agglutinating virus of Japan; Sendai virus) envelope (HVJ-E) vector using inactivated Sendai virus. The HVJ-E vector has been observed to target a number of cell lines since its hemagglutinin-neuraminidase (HN) protein recognizes the sialic acids of host cells. Thus, to reduce non-specific binding of the HVJ-E vector, we eliminated HN protein using HN-specific short interfering RNA (siRNA). Then, to further increase its tumor-targeting ability, we constructed HN-depleted HVJ containing the F-transferrin chimeric protein. The modified vectors containing Q-dots demonstrated 32-fold greater tumor-targeting efficiency than wildtype HVJ-E. (C) 2007 Elsevier Inc. All rights reserved.

引用

页码：423 / 428

页数：6

共 27 条

[1]

[Anonymous], POLYMERIC GENE DELIV

[2] The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer [J].

Daniels, Tracy R. ;

Delgado, Tracie ;

Rodriguez, Jose A. ;

Helguera, Gustavo ;

Penichet, Manuel L. .

CLINICAL IMMUNOLOGY, 2006, 121 (02) :144-158

[3] Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer [J].

Dass, CR .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (04) :177-181

[4] Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells [J].

Derycke, ASL ;

Kamuhabwa, A ;

Gijsens, A ;

Roskams, T ;

De Vos, D ;

Kasran, A ;

Huwyler, J ;

Missiaen, L ;

de Witte, PAM .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (21) :1620-1630

[5]

Everts M, 2004, CURR GENE THER, V4, P337

[6] Eradication of Renal Cell Carcinoma in Mice Mediated by NK Cell Activation Using Inactivated Sendai Virus Particle (HVJ-E) [J].

Fujihara, Atsuko ;

Kurooka, Masayuki ;

Miki, Tsuneharu ;

Kaneda, Yasufumi .

MOLECULAR THERAPY, 2006, 13 :S107-S107

[7] Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis [J].

Gardini, A ;

Ercolani, G ;

Riccobon, A ;

Ravaioli, M ;

Ridolfi, L ;

Flamini, E ;

Ridolfi, R ;

Grazi, GL ;

Cavallari, A ;

Amadori, D .

JOURNAL OF SURGICAL ONCOLOGY, 2004, 87 (01) :46-52

[8] Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer [J].

Iinuma, H ;

Maruyama, K ;

Okinaga, K ;

Sasaki, K ;

Sekine, T ;

Ishida, S ;

Ogiwara, N ;

Johkura, K ;

Yonemura, Y .

INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (01) :130-137

[9] Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo [J].

Ishida, O ;

Maruyama, K ;

Tanahashi, H ;

Iwatsuru, M ;

Sasaki, K ;

Eriguchi, M ;

Yanagie, H .

PHARMACEUTICAL RESEARCH, 2001, 18 (07) :1042-1048

[10] Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin [J].

Ito, M ;

Yamamoto, S ;

Nimura, K ;

Hiraoka, K ;

Tamai, K ;

Kaneda, Y .

JOURNAL OF GENE MEDICINE, 2005, 7 (08) :1044-1052

← 1 2 3 →